1
/
of
1
ELK Biotechnology
SKU:ES5321
Flt-3 (phospho Tyr842) rabbit pAb
Flt-3 (phospho Tyr842) rabbit pAb
Regular price
$250.00 USD
Regular price
Sale price
$250.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Applications: WB;ELISA
Reactivity: Human;Mouse
Source: Rabbit
Dilution: Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications.
Immunogen: The antiserum was produced against synthesized peptide derived from human FLT3 around the phosphorylation site of Tyr842. AA range:808-857
Storage_stability: -20°C/1 year
Clonality: Polyclonal
Isotype: IgG
Concentration: 1 mg/ml
Observed_band(KD): 170kD
Human_gene_id: 2322
Human_swiss_prot_no: P36888
Subcellular_location: Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation.
Other_name: FLT3; CD135; FLK2; STK1; Receptor-type tyrosine-protein kinase FLT3; FL cytokine receptor; Fetal liver kinase-2; FLK-2; Fms-like tyrosine kinase 3; FLT-3; Stem cell tyrosine kinase 1; STK-1; CD antigen CD135
Background: This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015],
Reactivity: Human;Mouse
Source: Rabbit
Dilution: Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications.
Immunogen: The antiserum was produced against synthesized peptide derived from human FLT3 around the phosphorylation site of Tyr842. AA range:808-857
Storage_stability: -20°C/1 year
Clonality: Polyclonal
Isotype: IgG
Concentration: 1 mg/ml
Observed_band(KD): 170kD
Human_gene_id: 2322
Human_swiss_prot_no: P36888
Subcellular_location: Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation.
Other_name: FLT3; CD135; FLK2; STK1; Receptor-type tyrosine-protein kinase FLT3; FL cytokine receptor; Fetal liver kinase-2; FLK-2; Fms-like tyrosine kinase 3; FLT-3; Stem cell tyrosine kinase 1; STK-1; CD antigen CD135
Background: This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015],
Share
